Literature DB >> 31792842

Consensus statement of the Hellenic and Cypriot Oesophageal Cancer Study Group on the diagnosis, staging and management of oesophageal cancer.

Andreas Fountoulakis1, John Souglakos2, Louiza Vini3, Gerasimos N Douridas4, Anna Koumarianou5, Panteleimon Kountourakis6, Christos Agalianos7, Andreas Alexandrou8, Christos Dervenis9, Sofia Gourtsoyianni10, Nikolaos Gouvas11, Maria-Angeliki Kalogeridi12, Georgia Levidou13, Theodoros Liakakos8, Joseph Sgouros14, Spiros N Sgouros15, Charikleia Triantopoulou16, Evangelos Xynos17.   

Abstract

In spite of recent advances in the diagnosis and management of oesophageal cancer, the overall survival of the disease worldwide remains disappointingly low. In Greece and Cyprus, this may be partly due to a failure of health care providers to implement standardised treatment protocols in clinical practice. Development of clinical practice guidelines was undertaken as a joint project between the Hellenic Society of Medical Oncology (HeSMO) and Gastro-Intestinal Cancer Study Group (GIC-SG) in an effort to provide guidance for Greek and Cypriot clinicians in all aspects of the management of oesophageal cancer. A study group was formed comprising clinicians from different disciplines with a special interest in the management of oesophageal cancer. Following extensive review of the literature, the members of the group met in person and consensus statements were developed, which were later subjected to the Delphi survey process by invited national and international experts. Statements that achieved a rate of voting consensus > 80% were adopted. Those that reached a voting consensus of < 80% were revised or rejected. In total, 46 sentences were developed and subjected to the voting process. Of those, 45 sentences achieved a rate of consensus > 80% during the first voting round. One sentence that did not reach a satisfactory rate of consensus was revised by the members of the study group and subsequently incorporated to the final statement. Forty-six recommendations covering all aspects of the management of oesophageal cancer and concise treatment algorithms are proposed by the Hellenic and Cypriot Oesophageal Cancer Study Group. In particular, centralisation of services, care by multidisciplinary teams and adherence to clinical guidelines are strongly recommended.

Entities:  

Keywords:  Adenocarcinoma; Carcinoma; Cyprus; Esophageal neoplasms; Greece; Guidelines; Squamous cell

Mesh:

Year:  2019        PMID: 31792842     DOI: 10.1007/s13304-019-00696-3

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  190 in total

1.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

2.  Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.

Authors:  Peter C Thuss-Patience; Manish A Shah; Atsushi Ohtsu; Eric Van Cutsem; Jaffer A Ajani; Hugo Castro; Wasat Mansoor; Hyun Cheol Chung; Gyorgy Bodoky; Kohei Shitara; Gail D Lewis Phillips; Tina van der Horst; Marie-Laurence Harle-Yge; Betsy L Althaus; Yoon-Koo Kang
Journal:  Lancet Oncol       Date:  2017-03-23       Impact factor: 41.316

3.  Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer.

Authors:  Thomas W Rice; Hemant Ishwaran; Mark K Ferguson; Eugene H Blackstone; Peter Goldstraw
Journal:  J Thorac Oncol       Date:  2016-10-31       Impact factor: 15.609

4.  Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

Authors:  J Randolph Hecht; Yung-Jue Bang; Shukui K Qin; Hyun C Chung; Jianming M Xu; Joon O Park; Krzysztof Jeziorski; Yaroslav Shparyk; Paulo M Hoff; Alberto Sobrero; Pamela Salman; Jin Li; Svetlana A Protsenko; Zev A Wainberg; Marc Buyse; Karen Afenjar; Vincent Houé; Agathe Garcia; Tomomi Kaneko; Yingjie Huang; Saba Khan-Wasti; Sergio Santillana; Michael F Press; Dennis Slamon
Journal:  J Clin Oncol       Date:  2015-11-30       Impact factor: 44.544

Review 5.  Clinical staging of esophageal carcinoma. CT, EUS, and PET.

Authors:  T W Rice
Journal:  Chest Surg Clin N Am       Date:  2000-08

6.  Use of a new jumbo forceps improves tissue acquisition of Barrett's esophagus surveillance biopsies.

Authors:  Sri Komanduri; Garth Swanson; Laurie Keefer; Shriram Jakate
Journal:  Gastrointest Endosc       Date:  2009-12       Impact factor: 9.427

7.  Prognostic Significance of the Location of Lymph Node Metastases in Patients With Adenocarcinoma of the Distal Esophagus or Gastroesophageal Junction.

Authors:  Maarten C J Anderegg; Sjoerd M Lagarde; Vamshi P Jagadesham; Suzanne S Gisbertz; Arul Immanuel; Sybren L Meijer; Maarten C C M Hulshof; Jacques J G H M Bergman; Hanneke W M van Laarhoven; S Michael Griffin; Mark I van Berge Henegouwen
Journal:  Ann Surg       Date:  2016-11       Impact factor: 12.969

Review 8.  Hospital and surgeon volume in relation to long-term survival after oesophagectomy: systematic review and meta-analysis.

Authors:  Nele Brusselaers; Fredrik Mattsson; Jesper Lagergren
Journal:  Gut       Date:  2013-11-22       Impact factor: 23.059

9.  Extent of lymphadenectomy in esophageal cancer: how many lymph nodes is enough?

Authors:  Luis J Herrera
Journal:  Ann Surg Oncol       Date:  2010-03       Impact factor: 5.344

10.  A randomised trial of endoscopic submucosal dissection versus endoscopic mucosal resection for early Barrett's neoplasia.

Authors:  Grischa Terheggen; Eva Maria Horn; Michael Vieth; Helmut Gabbert; Markus Enderle; Alexander Neugebauer; Brigitte Schumacher; Horst Neuhaus
Journal:  Gut       Date:  2016-01-22       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.